Efficacy and Safety of Dose Redution of Radotinib as a First Line Treament in Ph+ CML
Clinical trial NCT06665412 · RECRUITING
Trial details
- NCT number
- NCT06665412
- Sponsor
- Il-Yang Pharm. Co., Ltd.
- Status
- RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2024-10-24
- Primary completion
- 2026-09-30
- Enrollment
- 168
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.